There is little information about the use of bioresorbable vascular devices in patients with a reference diameter &ge;4mm, long, bifurcation, calcified or unstable lesions. The BVS-Expand registry is a single-center study that evaluates the safety and efficacy of this device in past populations (real world).The primary endpoint was the occurrence of MACE (cardiac death, myocardial<a href="https://solaci.org/en/2015/06/24/expand-expanding-the-applications-of-bioresorbable-platforms/" title="Read more" >...</a>

This balloon expandable stent is combined with a guide 0.014 in its distal part. The platform is made of cobalt chrome and the polymer is bio-degradable. 30 patients were included prospectively and there was angiographic follow-up with IVUS and OCT after 6 months. The reference vessel diameter was 2.69 mm &plusmn; 0.48, with a length<a href="https://solaci.org/en/2015/06/24/direct-results-of-drug-eluting-stent-on-a-wire-after-6-months/" title="Read more" >...</a>

This new device is a stainless steel platform of 120 &micro;m thick with a sirolimus-eluting bio-absorbable polymer. It has two separate parts: a larger diameter proximal part and a smaller diameter distal part connected by two 1.2 mm structures. The objective of this study was to test (first in man) the device in bifurcations. We<a href="https://solaci.org/en/2015/06/24/bioss-results-of-the-new-drug-eluting-stent-for-bifurcations/" title="Read more" >...</a>

This non-inferiority design study compared the sirolimus-eluting stent with biodegradable polymer versus everolimus-eluting stent with permanent polymer in de novo coronary lesions. The primary endpoint was late lumen loss at nine months. We Included 440 patients with stable coronary lesions randomized 2:1 to receive the new sirolimus eluting stent with biodegradable polymer versus everolimus eluting<a href="https://solaci.org/en/2015/06/24/bioflow-ii-stent-eluidor-de-sirolimus-com-polimero-degradavel/" title="Read more" >...</a>

This study is still in progress and includes patients using SYNTAX II score based on functional invasive evaluation with iFR / FFR and performing angioplasty guided by IVUS using the biodegradable polymer everolimus eluting stent. The study seeks to prove superiority versus the first generation paclitaxel-eluting stent and non-inferiority versus surgery using historical data. We<a href="https://solaci.org/en/2015/06/24/syntax-ii-multiple-vessels-using-ifr-ffr-and-ivus/" title="Read more" >...</a>

This new device consists of a novolimus releasing bioabsorbable polylactic acid platform that in vitro studies has shown equivalence to a Cypher stent. This device, also in vitro , showed a degradation time of one year and safety during post expansion, reaching 4.8 mm without fracturing. This is the first human trial and follow-up with<a href="https://solaci.org/en/2015/06/24/desolvenx-trial-results-of-the-new-bioabsorbable-platform/" title="Read more" >...</a>

This prospective randomized study compared aggressive revascularization angiography injuries 50% versus a most conservative revascularization lesions&gt;70%.The primary end point was death, myocardial infarction and recurring revascularization. We included a total of 889 patients (449 in the aggressive revascularization group and 450 in the conservative revascularization group).No differences in major cardiac events between the two groups<a href="https://solaci.org/en/2015/06/24/smart-case-angiographic-guidanceangioplastyto-50-versus-70-lesions/" title="Read more" >...</a>

This study randomized 1259 patients to receive one year versus 2 years of double anti anti-platelet after implantation of a drug-eluting stent. The primary end point was a composite of death, myocardial infarction, stroke, stent thrombosis, and urgent revascularization that were equivalent between the two schemes. There was a trend to a higher rate of<a href="https://solaci.org/en/2015/06/24/arctic-interruption-1-years-versus-2-years-of-double-anti-platelet/" title="Read more" >...</a>

The aim of this study was to compare the results of stent TRYTON (non-drug eluting) in the side branch associated with the implantation of a drug-eluting stent in the main branch compared to the drug-eluting stent implantation in the main branch with provisional stent technique.704 patients were included with the intention of demonstrating non-inferiority versus<a href="https://solaci.org/en/2015/06/24/tryton-stent-dedicated-to-bifurcations-fails-to-demonstrate-non-inferiority-when-compared-with-provisional/" title="Read more" >...</a>

Bivalirudin reduced mortality and bleeding compared to heparin and glycoprotein IIbIIIa in HORIZONS- AMI study. However there was a higher rate of acute stent thrombosis in patients receiving bivalirudin. This randomized study (&gt; 90 % randomized in the ambulance) enrolled 2218 patients with ASTEMIto prolonged infusion of bivalirudin compared with heparin -associated glycoprotein inhibitors. The<a href="https://solaci.org/en/2015/06/24/euromax-early-and-prolonged-infusion-of-bivalirudin-reduces-mortality-in-ami/" title="Read more" >...</a>